File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population
  • Basic View
  • Metadata View
  • XML View
TitleAdefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population
 
AuthorsFung, J1
Lai, CL1
Yuen, JCH1
Wong, DKH1
Tanaka, Y2
Mizokami, M2
Yuen, MF1
 
Issue Date2007
 
PublisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm
 
CitationAntiviral Therapy, 2007, v. 12 n. 1, p. 41-46 [How to Cite?]
 
AbstractAim: To determine differences in Chinese patients treated with adefovir (ADV) monotherapy or ADV in combination with lamivudine (3TC) after development of resistance to 3TC, with respect to biochemical improvement, HBV DNA suppression and development of subsequent ADV resistance. Methods: All hepatitis B patients with 3TC resistance treated with ADV for 3 months or more at our centre were included, and monitored 3-6 monthly for biochemical and virological response, and development of ADV resistance. Results: A total of 56 patients were included, 50% switched to ADV monotherapy and 50% received combination 3TC/ADV therapy. Median follow-up was 15.5 months. Normalization of alanine aminotransferase (ALT) occurred in 25 (89%) patients in the ADV group compared with 24 (86%) in the 3TC/ADV group (P=0.686). Virological response (VR) was achieved in seven (35%) patients in the ADV group at 12 months compared with five (28%) in the 3TC/ADV group (P=0.637). By 24 months, seven (64%) patients in the ADV group achieved VR compared with two (40%) in the 3TC/ADV group (P=0.377). Cumulative probability of developing genotypic ADV resistance in the ADV group at 24 months was 18% compared with 7% in the 3TC/ADV group (P=0.94). Conclusion: There was no obvious improvement in ALT normalization and virological suppression or reduction in the development of ADV-resistant mutations with 3TC/ADV therapy compared with ADV monotherapy. Further studies with longer follow-ups are required to determine whether combination 3TC/ADV therapy will reduce the emergence of ADV resistance compared with ADV monotherapy. © 2007 International Medical Press.
 
ISSN1359-6535
2013 Impact Factor: 3.143
2013 SCImago Journal Rankings: 1.542
 
ISI Accession Number IDWOS:000247111200006
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorFung, J
 
dc.contributor.authorLai, CL
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorTanaka, Y
 
dc.contributor.authorMizokami, M
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2010-09-06T07:39:33Z
 
dc.date.available2010-09-06T07:39:33Z
 
dc.date.issued2007
 
dc.description.abstractAim: To determine differences in Chinese patients treated with adefovir (ADV) monotherapy or ADV in combination with lamivudine (3TC) after development of resistance to 3TC, with respect to biochemical improvement, HBV DNA suppression and development of subsequent ADV resistance. Methods: All hepatitis B patients with 3TC resistance treated with ADV for 3 months or more at our centre were included, and monitored 3-6 monthly for biochemical and virological response, and development of ADV resistance. Results: A total of 56 patients were included, 50% switched to ADV monotherapy and 50% received combination 3TC/ADV therapy. Median follow-up was 15.5 months. Normalization of alanine aminotransferase (ALT) occurred in 25 (89%) patients in the ADV group compared with 24 (86%) in the 3TC/ADV group (P=0.686). Virological response (VR) was achieved in seven (35%) patients in the ADV group at 12 months compared with five (28%) in the 3TC/ADV group (P=0.637). By 24 months, seven (64%) patients in the ADV group achieved VR compared with two (40%) in the 3TC/ADV group (P=0.377). Cumulative probability of developing genotypic ADV resistance in the ADV group at 24 months was 18% compared with 7% in the 3TC/ADV group (P=0.94). Conclusion: There was no obvious improvement in ALT normalization and virological suppression or reduction in the development of ADV-resistant mutations with 3TC/ADV therapy compared with ADV monotherapy. Further studies with longer follow-ups are required to determine whether combination 3TC/ADV therapy will reduce the emergence of ADV resistance compared with ADV monotherapy. © 2007 International Medical Press.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationAntiviral Therapy, 2007, v. 12 n. 1, p. 41-46 [How to Cite?]
 
dc.identifier.epage46
 
dc.identifier.hkuros130669
 
dc.identifier.isiWOS:000247111200006
 
dc.identifier.issn1359-6535
2013 Impact Factor: 3.143
2013 SCImago Journal Rankings: 1.542
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid17503746
 
dc.identifier.scopuseid_2-s2.0-33847358124
 
dc.identifier.spage41
 
dc.identifier.urihttp://hdl.handle.net/10722/78135
 
dc.identifier.volume12
 
dc.languageeng
 
dc.publisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofAntiviral Therapy
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdenine - analogs & derivatives - therapeutic use
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAlanine Transaminase - blood
 
dc.subject.meshAsian Continental Ancestry Group
 
dc.subject.meshDNA, Viral - blood
 
dc.subject.meshDrug Resistance, Multiple, Viral - genetics
 
dc.subject.meshDrug Therapy, Combination
 
dc.subject.meshFemale
 
dc.subject.meshFollow-Up Studies
 
dc.subject.meshGenotype
 
dc.subject.meshHepatitis B virus - genetics
 
dc.subject.meshHepatitis B, Chronic - blood - drug therapy - genetics
 
dc.subject.meshHong Kong
 
dc.subject.meshHumans
 
dc.subject.meshLamivudine - therapeutic use
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPhosphonic Acids - therapeutic use
 
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic use
 
dc.subject.meshTime Factors
 
dc.subject.meshTreatment Outcome
 
dc.subject.meshViral Load
 
dc.titleAdefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fung, J</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Tanaka, Y</contributor.author>
<contributor.author>Mizokami, M</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2010-09-06T07:39:33Z</date.accessioned>
<date.available>2010-09-06T07:39:33Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Antiviral Therapy, 2007, v. 12 n. 1, p. 41-46</identifier.citation>
<identifier.issn>1359-6535</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/78135</identifier.uri>
<description.abstract>Aim: To determine differences in Chinese patients treated with adefovir (ADV) monotherapy or ADV in combination with lamivudine (3TC) after development of resistance to 3TC, with respect to biochemical improvement, HBV DNA suppression and development of subsequent ADV resistance. Methods: All hepatitis B patients with 3TC resistance treated with ADV for 3 months or more at our centre were included, and monitored 3-6 monthly for biochemical and virological response, and development of ADV resistance. Results: A total of 56 patients were included, 50% switched to ADV monotherapy and 50% received combination 3TC/ADV therapy. Median follow-up was 15.5 months. Normalization of alanine aminotransferase (ALT) occurred in 25 (89%) patients in the ADV group compared with 24 (86%) in the 3TC/ADV group (P=0.686). Virological response (VR) was achieved in seven (35%) patients in the ADV group at 12 months compared with five (28%) in the 3TC/ADV group (P=0.637). By 24 months, seven (64%) patients in the ADV group achieved VR compared with two (40%) in the 3TC/ADV group (P=0.377). Cumulative probability of developing genotypic ADV resistance in the ADV group at 24 months was 18% compared with 7% in the 3TC/ADV group (P=0.94). Conclusion: There was no obvious improvement in ALT normalization and virological suppression or reduction in the development of ADV-resistant mutations with 3TC/ADV therapy compared with ADV monotherapy. Further studies with longer follow-ups are required to determine whether combination 3TC/ADV therapy will reduce the emergence of ADV resistance compared with ADV monotherapy. &#169; 2007 International Medical Press.</description.abstract>
<language>eng</language>
<publisher>International Medical Press. The Journal&apos;s web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm</publisher>
<relation.ispartof>Antiviral Therapy</relation.ispartof>
<subject.mesh>Adenine - analogs &amp; derivatives - therapeutic use</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Alanine Transaminase - blood</subject.mesh>
<subject.mesh>Asian Continental Ancestry Group</subject.mesh>
<subject.mesh>DNA, Viral - blood</subject.mesh>
<subject.mesh>Drug Resistance, Multiple, Viral - genetics</subject.mesh>
<subject.mesh>Drug Therapy, Combination</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Follow-Up Studies</subject.mesh>
<subject.mesh>Genotype</subject.mesh>
<subject.mesh>Hepatitis B virus - genetics</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - blood - drug therapy - genetics</subject.mesh>
<subject.mesh>Hong Kong</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Lamivudine - therapeutic use</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Phosphonic Acids - therapeutic use</subject.mesh>
<subject.mesh>Reverse Transcriptase Inhibitors - therapeutic use</subject.mesh>
<subject.mesh>Time Factors</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<subject.mesh>Viral Load</subject.mesh>
<title>Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1359-6535&amp;volume=12&amp;spage=41&amp;epage=46&amp;date=2007&amp;atitle=Adefovir+dipivoxil+monotherapy+and+combination+therapy+with+lamivudine+for+the+treatment+of+chronic+hepatitis+B+in+an+Asian+population</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.pmid>17503746</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33847358124</identifier.scopus>
<identifier.hkuros>130669</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33847358124&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>12</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>41</identifier.spage>
<identifier.epage>46</identifier.epage>
<identifier.isi>WOS:000247111200006</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Nagoya City University Graduate School of Medical Sciences